A Literature Review on Hospital-Acquired Pneumonia, Community-Acquired Pneumonia, and Ventilator-Associated Pneumonia

authors:

avatar Pedram Bolboli Zade 1 , avatar Abbas Farahani 2 , * , avatar Mohammadreza Riyahi 1 , avatar Ali Lalabadi 1 , avatar Ali Salimi Asl 3 , avatar Sobhan Montazerghaem 3 , **

Student Research Committee, Faculty of Para Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
Student Research Committee, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
Corresponding Authors:

how to cite: Bolboli Zade P, Farahani A, Riyahi M , Lalabadi A, Salimi Asl A, et al. A Literature Review on Hospital-Acquired Pneumonia, Community-Acquired Pneumonia, and Ventilator-Associated Pneumonia. Gene Cell Tissue. 2022;9(2):e116869. doi: 10.5812/gct.116869.

Abstract

One of the most dangerous respiratory diseases is pneumonia, one of the ten leading causes of death globally. Hospital-acquired pneumonia (HAP) is a common infection in hospitals, which is the second most common nosocomial infection and causes inflammation parenchyma. In community-acquired pneumonia (CAP), we have various risk factors, including age and gender, and also some specific risk factors. Ventilator-associated pneumonia (VAP) is one of the deadliest nosocomial infections. According to the Centers for Disease Control and Prevention, VAP is pneumonia that develops about 48 hours of an artificial airway. Bacteria, viruses, parasites, fungi, and other microorganisms can cause these diseases. This review article discusses microbial agents associated with pneumonia. Our goal is to gather information about HAP, CAP, and VAP to give people specific information. In this study, these three issues have been examined together, but in similar studies, each of them has been examined separately, and our type of study will be more helpful in diagnosis and treatment.

1. Background

Respiratory diseases are among the most frequent causes of death due to their high diversity of risk factors, and their risk factors originate from various organisms, each of which causes specific clinical features (1). Respiratory diseases are considered diseases of the airways and other parts of the lungs, including obstructive diseases, restrictive diseases, and vascular diseases (1). Each of these diseases can be caused by a wide variety of bacteria, viruses, parasites, fungi, and other microorganisms (1, 2). We discuss bacterial factors. One of the most dangerous respiratory diseases is pneumonia, one in all the ten leading causes of death globally and is the most important infectious killer for children under five (3, 4).

Hospital-acquired pneumonia (HAP) is a common infection in hospitals, which is the second most common nosocomial infection and causes inflammation parenchyma. HAP is usually found in patients who have been in the intensive care unit (ICU) for at least 48 hours (5, 6). In community-acquired pneumonia (CAP), there are various risk factors, including age and gender, and some specific risk factors such as autoimmune and heart diseases, which affect the identification of the cause. We can identify these differences using some information such as etiology that we can get from different subjects (7, 8). Ventilator-associated pneumonia (VAP) is one of the deadliest nosocomial infections. According to the Centers for Disease Control and Prevention (CDC), VAP is pneumonia that develops within 48 hours of an artificial airway (9).

One of the characteristics of VAP in most studies is that it occurs within 48 to 72 hours (or more than 48 hours) (10) after the placement of artificial airways for mechanical ventilation (MV) on the patient. The incidence of VAP in patients with MV has been reported to be up to 40%. One of the differences between the definition of VAP and Hospital-acquired pneumonia or HAP is that HAP, unlike VAP, is not associated with MV (11, 12).

2. Etiology

The causative agents of HAP may be Streptococcus pneumoniae, Staphylococcus aureus, and strains of Gram-negative bacteria (GNB) such as Pseudomonas aeruginosa (PA) and Klebsiella pneumoniae (5, 13-16). Researchers showed that the type of microorganism that HAP patients are affected by them, can be various in different residential areas (5, 17, 18). As soon as MV and intubation are applied, these artificial airways become a breeding ground for microorganisms (15, 19). VAP is usually caused by a microorganism, which is usually a bacterium; According to studies, the most common causes of VAP are PA, Acinetobacter baumannii, K. pneumoniae, and S. aureus (including MRSA). It has also been suggested that the disease-causing microorganisms observed in respiratory secretions are mainly Gram-negative bacilli. In addition to the above, Escherichia coli with high drug resistance has also been observed (9, 11, 20, 21).

Anaerobic bacteria are uncommon causes of VAP. They can be involved in polymicrobial infections, especially in respiratory pneumonia. Also, pneumonia related to nosocomial fungal and viral infections are the main causes of mortality in immunocompromised patients (21). Data show that although the major pathogens are similar in both HAP and VAP, antimicrobial susceptibility is lower in VAP. This is especially true about PA. Statistics show that the 30-day mortality rate is about 15 to 20% in HAP and is between 40 and 45% in VAP (12).

3. Risk Factor

In addition to the predisposition factors to the disease such as age and gender, there are risk factors such as a history of chest and abdomen surgery and hospitalization, renal and pulmonary disorders, diabetes mellitus, and smoking. They can increase the risk of HAP (18, 22-24). More severe HAP cases have been reported due to the development of drug and antibiotic resistance in HAP-causing microorganisms, including multi-drug resistant PA (MDR_PA) (17, 23, 25). Prolonged hospitalization, the use of inappropriate broad-spectrum antibiotics, and immunosuppressive drugs likely facilitate the development of drug-resistant microorganisms that cause more deaths in HAP patients (16-18, 22). Evidence suggests a low neutrophil-lymphocyte ratio (NLR) may be a risk factor for MDR_PA (with low NLR can be expected to get MDR_PA) (17, 23, 25).

Many risk factors can cause CAP, as mentioned, the general risk factors that can be mentioned are age and gender and some more specific risk factors, including cardiovascular diseases, renal disorders that affect the activity of enzymes and hormones, and the endocrine glands in the body (17, 19, 26, 27). Other specific risk factors consist of neurological diseases such as autoimmune diseases, which are one of the most important risk factors (10, 26, 28). Lung diseases provide the environment for the CAP in a way that is a significant risk factor, and these diseases increase the likelihood of the patient being hospitalized for twenty to thirty days (14, 19, 27, 29, 30).

Some risk factors, such as air pollution, depend on the patient's environment (10, 29). VAP incidence depends on the duration of exposure to the hospital and ICU environment, host factors and characteristics, and therapeutic factors that may lead to VAP (8, 21). Also, risk factors that increase the likelihood of colonization in canals and tubes by bacterial pathogens (such as previous exposure to antibiotics, age over 60, and chronic obstructive pulmonary disease (COPD) as well as secretion respiration. Infections should be considered when sleeping on your back, coma, and head trauma (31). Gender, length of hospital stay, MV, duration of MV, and aspiration and reflux are among the risk factors associated with VAP occurrence in the ICU (9). Possibly, the leading risk factor in creating and developing VAP is MV. Some data suggest a decrease in antibacterial activity of Th17 in the lung in response to MV prolongation, which is associated with the VAP progression (32). Other risk factors associated with VAP progression include COPD, organ failure, coma, and re-intubation. Chronic obstructive pulmonary disease has been recognized as an independent risk factor for VAP, and statistics show that more than 50% of COPD patients who develop VAP succumb to it (11). Elderly patients with coma and diabetes mellitus require special supervision. Also, comprehensive control and prevention of risk factors in all aspects can control the rate of VAP occurrence and improve its prediction (9).

4. Clinical Presentation

After infection, the clinical symptoms of patients manifest with pneumonia, impaired breathing and oxygenation of tissues, and the formation of purulent sputum in the respiratory tract (33). Also, the number of WBCs and markers such as C-reactive protein (CRP) in patients increases, which indicates the presence of inflammation and damage in the body (2, 29). In patients with autoimmune disease associated with CAP, we see kidney failure and difficulty in ventilation, and we see various problems in the respiratory system that expel it in the form of pus (27, 28). Cough, sputum, fever, breathlessness are common clinical features that can be mentioned in patients. Moreover, VAP usually has no specific clinical features and is usually characterized by the presence or development of new secretions in the lungs and signs of a systemic infection that includes fever, changes in the number of white blood cells (leukopenia, and leukocytosis). Changes in the characteristics of sputum and the presence of pathogens can also be its characteristics. Other clinical findings include pulmonary discharge and worsening gas exchange (21).

5. Diagnostics

Non-invasive diagnosis of HAP is made by methods such as using the patient's respiratory secretions for polymerase chain reaction (PCR), sputum and blood culture, and invasive methods such as bronchoalveolar lavage (BAL) (33-37). Using methods such as X-ray imaging or newer methods such as lung ultrasound can detect the appearance of infection in the lung tissue (30). The most common treatments for patients are strong antibiotics. According to the findings, the use of appropriate antibiotics before the disease progresses, along with ensuring the accuracy of HAP in the patient is a factor that contributes to the progression and effectiveness of the treatment (33, 38).

It is very important to diagnose the patient's medical history and physical examination, and some clinical manifestations can be non-specific, and a device such as a chest X-ray (CXR) and Computed tomography (CT) can help make a definitive diagnosis (31). However, these also have some limitations. Recently, the use of ultrasound is also increasing because it does not have some limitations of CXR and CT. Ultrasound is introduced as an alternative method and must be accompanied by the patient's history, clinical examination, and laboratory analysis. Ultrasound also needs experienced staff (31). Gold standard VAP diagnostic tests are still incomplete in some places, and there is no clear and reference evidence for the order of diagnostic tests and their exact effects on the clinical condition (39).

According to the criteria, the clinical diagnosis of VAP, CAP, and HAP is based on the observation of new or advanced pulmonary leakage on radiography without any previous cause and at least two cases of fever more than 38 degrees, leukocytosis more than 12,000 per deciliter, less leukopenia from 4,000 per deciliter, pulmonary secretion, isolate pathogenic pathogens and increase oxygen demand (11). Markers used for diagnosis include WBC and CRP and sequential organ failure assessment scores. Patients diagnosed with VAP have been found to have higher levels of CRP and procalcitonin (PCT) (11, 39, 40). Procalcitonin is also one of the measured indicators, but in VAP, unlike CAP, PCT level measurement alone cannot be a good biomarker for VAP diagnosis. Also, the combination of lung ultrasound with PCT in diagnosis is accurate and useful. Lavage (BAL) is another common tool used for VAP detection (34).

According to a study conducted in collaboration with a panel of European experts, a classification of diagnostic tools has been obtained. In this study, CXR was introduced as the most significant imaging technique. Apart from blood culture, endotracheal aspirate culture was introduced as the main collection method in microbiological tests. Also, Mini-BAL was introduced as the most accepted invasive technique and Gram stain as the most accepted laboratory technique. The top three biomarkers in this category were CRP, PCT, and WBC, respectively. The study suggested combining imaging, culture of clinical specimens, and using biomarkers to diagnose VAP (39). Timing of diagnosis and prognosis is a serious challenge in hospitals, especially in the ICU. Due to the high mortality rate due to VAP, as well as other cases, early detection with high accuracy can be crucial. Low-specificity diagnostic tests can lead to misdiagnosis, severe nosocomial infections, and increased mortality. Therefore, updating cases and diagnostic methods and providing new solutions with high accuracy have been studied by many researchers (40). For example, one study found that measuring trigeminal receptor expression expressed on myeloid cells 1 (sTERM-1) in serum plus clinical pulmonary infection score (CPIS) is useful in diagnosing and measuring PCT plus CPIS in prognostics assessment (40).

6. Limitations

Due to the limited database, many issues are not mentioned or subheadlines are not fully explained and are summarized, which increases the likelihood of inaccuracy. Some of the information could not be accessed, and due to the widespread of the selected topic, it was not possible to use accurate statistics.

7. Conclusion

By collecting information about pneumonia, we can increase awareness about the disease. By knowing the characteristics of hospital-acquired pneumonia (HAP), community-acquired pneumonia (CAP), and ventilator-associated pneumonia (VAP), we can prevent or treat them. The simplicity of the information and the type of writing also helps to understand better the public, which makes this information not specific to a particular group, and everyone can use and understand it. In this study, these three issues have been examined together, but in similar studies, each of them has been examined separately, and our type of study will be more helpful in diagnosis and treatment.

References

  • 1.

    Chinnapaiyan S, Dutta RK, Unwalla HJ. Novel Approaches of CRISPR-Cas Technology in Airway Diseases. Crit Rev Biomed Eng. 2020;48(3):169-76. doi: 10.1615/CritRevBiomedEng.2020034594. [PubMed: 33389894].

  • 2.

    Bhuiyan MU, Blyth CC, West R, Lang J, Rahman T, Granland C, et al. Combination of clinical symptoms and blood biomarkers can improve discrimination between bacterial or viral community-acquired pneumonia in children. BMC Pulm Med. 2019;19(1):71. doi: 10.1186/s12890-019-0835-5. [PubMed: 30940126]. [PubMed Central: PMC6444754].

  • 3.

    Jang JG, Ahn JH. Reasons and Risk Factors for Readmission Following Hospitalization for Community-acquired Pneumonia in South Korea. Tuberc Respir Dis (Seoul). 2020;83(2):147-56. doi: 10.4046/trd.2019.0073. [PubMed: 32185918]. [PubMed Central: PMC7105431].

  • 4.

    Yun KW, Wallihan R, Juergensen A, Mejias A, Ramilo O. Community-Acquired Pneumonia in Children: Myths and Facts. Am J Perinatol. 2019;36(S 02):S54-7. doi: 10.1055/s-0039-1691801. [PubMed: 31238360].

  • 5.

    Feng DY, Zhou YQ, Zou XL, Zhou M, Wu WB, Chen XX, et al. Factors influencing mortality in hospital-acquired pneumonia caused by Gram-negative bacteria in China. J Infect Public Health. 2019;12(5):630-3. doi: 10.1016/j.jiph.2019.02.014. [PubMed: 30824328].

  • 6.

    Min JY, Kim HJ, Yoon C, Lee K, Yeo M, Min KB. Hospital-Acquired Pneumonia among Inpatients via the Emergency Department: A Propensity-Score Matched Analysis. Int J Environ Res Public Health. 2018;15(6). doi: 10.3390/ijerph15061178. [PubMed: 29874845]. [PubMed Central: PMC6024900].

  • 7.

    Abelenda-Alonso G, Rombauts A, Gudiol C, Meije Y, Ortega L, Clemente M, et al. Influenza and Bacterial Coinfection in Adults With Community-Acquired Pneumonia Admitted to Conventional Wards: Risk Factors, Clinical Features, and Outcomes. Open Forum Infect Dis. 2020;7(3):ofaa066. doi: 10.1093/ofid/ofaa066. [PubMed: 32206675]. [PubMed Central: PMC7081386].

  • 8.

    Zhang X, Liu B, Liu Y, Ma L, Zeng H. Efficacy of the quick sequential organ failure assessment for predicting clinical outcomes among community-acquired pneumonia patients presenting in the emergency department. BMC Infect Dis. 2020;20(1):316. doi: 10.1186/s12879-020-05044-0. [PubMed: 32349682]. [PubMed Central: PMC7191824].

  • 9.

    Zhang J, Deng R, Jia H, Li X. Risk factors and peripheral blood lymphocyte subset analysis of patients with ventilator-associated pneumonia: A Chinese population-based study. Int J Clin Exp Pathol. 2019;12(10):3830-8. [PubMed: 31933771]. [PubMed Central: PMC6949756].

  • 10.

    Muthumbi E, Lowe BS, Muyodi C, Getambu E, Gleeson F, Scott JAG. Risk factors for community-acquired pneumonia among adults in Kenya: A case-control study. Pneumonia (Nathan). 2017;9:17. doi: 10.1186/s41479-017-0041-2. [PubMed: 29209590]. [PubMed Central: PMC5702239].

  • 11.

    Khilnani GC, Dubey D, Hadda V, Sahu SR, Sood S, Madan K, et al. Predictors and microbiology of ventilator-associated pneumonia among patients with exacerbation of chronic obstructive pulmonary disease. Lung India. 2019;36(6):506-11. doi: 10.4103/lungindia.lungindia_13_19. [PubMed: 31670298]. [PubMed Central: PMC6852209].

  • 12.

    Feng DY, Zhou YQ, Zou XL, Zhou M, Zhu JX, Wang YH, et al. Differences in microbial etiology between hospital-acquired pneumonia and ventilator-associated pneumonia: A single-center retrospective study in Guang Zhou. Infect Drug Resist. 2019;12:993-1000. doi: 10.2147/IDR.S204671. [PubMed: 31118705]. [PubMed Central: PMC6503191].

  • 13.

    Para RA, Fomda BA, Jan RA, Shah S, Koul PA. Microbial etiology in hospitalized North Indian adults with community-acquired pneumonia. Lung India. 2018;35(2):108-15. doi: 10.4103/lungindia.lungindia_288_17. [PubMed: 29487244]. [PubMed Central: PMC5846258].

  • 14.

    Restrepo MI, Babu BL, Reyes LF, Chalmers JD, Soni NJ, Sibila O, et al. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: A multinational point prevalence study of hospitalised patients. Eur Respir J. 2018;52(2). doi: 10.1183/13993003.01190-2017. [PubMed: 29976651].

  • 15.

    Ning G, Wang X, Wu D, Yin Z, Li Y, Wang H, et al. The etiology of community-acquired pneumonia among children under 5 years of age in mainland China, 2001-2015: A systematic review. Hum Vaccin Immunother. 2017;13(11):2742-50. doi: 10.1080/21645515.2017.1371381. [PubMed: 28922613]. [PubMed Central: PMC5703373].

  • 16.

    Zhou YQ, Feng DY, Li WJ, Yang HL, Wang ZN, Zhang TT, et al. Lower neutrophil-to-lymphocyte ratio predicts high risk of multidrug-resistant Pseudomonas aeruginosa infection in patients with hospital-acquired pneumonia. Ther Clin Risk Manag. 2018;14:1863-9. doi: 10.2147/TCRM.S179181. [PubMed: 30323608]. [PubMed Central: PMC6174305].

  • 17.

    Haque NZ, Arshad S, Peyrani P, Ford KD, Perri MB, Jacobsen G, et al. Analysis of pathogen and host factors related to clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2012;50(5):1640-4. doi: 10.1128/JCM.06701-11. [PubMed: 22337980]. [PubMed Central: PMC3347104].

  • 18.

    Luyt CE, Hekimian G, Koulenti D, Chastre J. Microbial cause of ICU-acquired pneumonia: hospital-acquired pneumonia versus ventilator-associated pneumonia. Curr Opin Crit Care. 2018;24(5):332-8. doi: 10.1097/MCC.0000000000000526. [PubMed: 30036192].

  • 19.

    Aston SJ, Ho A, Jary H, Huwa J, Mitchell T, Ibitoye S, et al. Etiology and Risk Factors for Mortality in an Adult Community-acquired Pneumonia Cohort in Malawi. Am J Respir Crit Care Med. 2019;200(3):359-69. doi: 10.1164/rccm.201807-1333OC. [PubMed: 30625278]. [PubMed Central: PMC6680311].

  • 20.

    Hassoun-Kheir N, Hussein K, Abboud Z, Raderman Y, Abu-Hanna L, Darawshe A, et al. "Risk factors for ventilator-associated pneumonia following cardiac surgery: Case-control study". J Hosp Infect. 2020. doi: 10.1016/j.jhin.2020.04.009. [PubMed: 32283174].

  • 21.

    Kohbodi GNA, Rajasurya V, Noor A. Ventilator-associated Pneumonia. Treasure Island (FL): StatPearls; 2021.

  • 22.

    Stenlund M, Sjodahl R, Pia Yngman-Uhlin RN. Incidence and potential risk factors for hospital-acquired pneumonia in an emergency department of surgery. Int J Qual Health Care. 2017;29(2):290-4. doi: 10.1093/intqhc/mzx018. [PubMed: 28339769].

  • 23.

    Sopena N, Heras E, Casas I, Bechini J, Guasch I, Pedro-Botet ML, et al. Risk factors for hospital-acquired pneumonia outside the intensive care unit: a case-control study. Am J Infect Control. 2014;42(1):38-42. doi: 10.1016/j.ajic.2013.06.021. [PubMed: 24199911].

  • 24.

    Erb CT, Patel B, Orr JE, Bice T, Richards JB, Metersky ML, et al. Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia. Ann Am Thorac Soc. 2016;13(12):2258-60. doi: 10.1513/AnnalsATS.201608-641CME. [PubMed: 27925784].

  • 25.

    Seligman R, Ramos-Lima LF, Oliveira Vdo A, Sanvicente C, Sartori J, Pacheco EF. Risk factors for infection with multidrug-resistant bacteria in non-ventilated patients with hospital-acquired pneumonia. J Bras Pneumol. 2013;39(3):339-48. doi: 10.1590/S1806-37132013000300011. [PubMed: 23857697]. [PubMed Central: PMC4075848].

  • 26.

    Garcia Garrido HM, Mak AMR, Wit F, Wong GWM, Knol MJ, Vollaard A, et al. Incidence and Risk Factors for Invasive Pneumococcal Disease and Community-acquired Pneumonia in Human Immunodeficiency Virus-Infected Individuals in a High-income Setting. Clin Infect Dis. 2020;71(1):41-50. doi: 10.1093/cid/ciz728. [PubMed: 31634398]. [PubMed Central: PMC7312213].

  • 27.

    Echaniz-Aviles G, Garza-Gonzalez E, Roman-Mancha AL, Morfin-Otero R, Rodriguez-Noriega E, Ayala-Gaytan JJ, et al. Clinical and microbiological characteristics of community-acquired pneumonia associated with Streptococcus pneumoniae in adult patients in Mexico. Rev Argent Microbiol. 2019;51(3):234-40. doi: 10.1016/j.ram.2018.10.002. [PubMed: 30635204].

  • 28.

    Kuang ZS, Yang YL, Wei W, Wang JL, Long XY, Li KY, et al. Clinical characteristics and prognosis of community-acquired pneumonia in autoimmune disease-induced immunocompromised host: A retrospective observational study. World J Emerg Med. 2020;11(3):145-51. doi: 10.5847/wjem.j.1920-8642.2020.03.003. [PubMed: 32351646]. [PubMed Central: PMC7183923].

  • 29.

    Yu-Qing W, Chuang-Li H, Wei J, Zheng-Rong C, Xin-Xin Z, Wen-Jing G. Etiology and Clinical Characteristics of Community-Acquired Pneumonia with Airway Malacia in Children. J Trop Pediatr. 2018;64(4):317-25. doi: 10.1093/tropej/fmx071. [PubMed: 29036724].

  • 30.

    Huang WC, Lee CH, Wu MF, Huang CC, Hsu CH, Chen HC, et al. Clinical features, bacteriology of endotracheal aspirates and treatment outcomes of patients with chronic obstructive pulmonary disease and community-acquired pneumonia in an intensive care unit in Taiwan with an emphasis on eosinophilia versus non-eosinophilia: a retrospective case-control study. BMJ Open. 2018;8(9). e020341. doi: 10.1136/bmjopen-2017-020341. [PubMed: 30206074]. [PubMed Central: PMC6144339].

  • 31.

    Zhao X, Feng J, Zhang L, Zhao F, Li M, Du Y, et al. One functional variant in the 3'-untranslated region of TLR4 is associated with the elevated risk of ventilator-associated pneumonia in the patients with chronic obstructive pulmonary disease. J Cell Physiol. 2019;234(10):18879-86. doi: 10.1002/jcp.28526. [PubMed: 30972742].

  • 32.

    De Winter FHR, s Jongers B, Bielen K, Mancuso D, Timbermont L, Lammens C, et al. Mechanical Ventilation Impairs IL-17 Cytokine Family Expression in Ventilator-Associated Pneumonia. Int J Mol Sci. 2019;20(20). doi: 10.3390/ijms20205072. [PubMed: 31614857]. [PubMed Central: PMC6829394].

  • 33.

    Russell CD, Koch O, Laurenson IF, O'Shea DT, Sutherland R, Mackintosh CL. Diagnosis and features of hospital-acquired pneumonia: a retrospective cohort study. J Hosp Infect. 2016;92(3):273-9. doi: 10.1016/j.jhin.2015.11.013. [PubMed: 26810613]. [PubMed Central: PMC7172606].

  • 34.

    Harrell KN, Reynolds JK, Wilks GR, Stanley JD, Dart B, Maxwell RA. The Effect of Lung Lavage Volume Return on the Diagnosis of Ventilator-Associated Pneumonia. J Surg Res. 2020;248:56-61. doi: 10.1016/j.jss.2019.11.016. [PubMed: 31865159].

  • 35.

    Kunze N, Moerer O, Steinmetz N, Schulze MH, Quintel M, Perl T. Point-of-care multiplex PCR promises short turnaround times for microbial testing in hospital-acquired pneumonia--an observational pilot study in critical ill patients. Ann Clin Microbiol Antimicrob. 2015;14:33. doi: 10.1186/s12941-015-0091-3. [PubMed: 26071191]. [PubMed Central: PMC4469099].

  • 36.

    Eccles S, Pincus C, Higgins B, Woodhead M; Guideline Development Group. Diagnosis and management of community and hospital acquired pneumonia in adults: summary of NICE guidance. BMJ. 2014;349:g6722. doi: 10.1136/bmj.g6722. [PubMed: 25471702].

  • 37.

    Ewan VC, Sails AD, Walls AW, Rushton S, Newton JL. Dental and microbiological risk factors for hospital-acquired pneumonia in non-ventilated older patients. PLoS One. 2015;10(4). e0123622. doi: 10.1371/journal.pone.0123622. [PubMed: 25923662]. [PubMed Central: PMC4414413].

  • 38.

    Ranzani OT, De Pascale G, Park M. Diagnosis of nonventilated hospital-acquired pneumonia: How much do we know? Curr Opin Crit Care. 2018;24(5):339-46. doi: 10.1097/MCC.0000000000000525. [PubMed: 30028740].

  • 39.

    Ferreira-Coimbra J, Ardanuy C, Diaz E, Leone M, De Pascale G, Povoa P, et al. Ventilator-associated pneumonia diagnosis: A prioritization exercise based on multi-criteria decision analysis. Eur J Clin Microbiol Infect Dis. 2020;39(2):281-6. doi: 10.1007/s10096-019-03720-x. [PubMed: 31654147]. [PubMed Central: PMC7223949].

  • 40.

    Su LX, Meng K, Zhang X, Wang HJ, Yan P, Jia YH, et al. Diagnosing ventilator-associated pneumonia in critically ill patients with sepsis. Am J Crit Care. 2012;21(6):e110-9. doi: 10.4037/ajcc2012732. [PubMed: 23117911].

Copyright © 2021, Gene, Cell and Tissue. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.